ES2849187T3 - Método para activar células T auxiliares - Google Patents

Método para activar células T auxiliares Download PDF

Info

Publication number
ES2849187T3
ES2849187T3 ES11830662T ES11830662T ES2849187T3 ES 2849187 T3 ES2849187 T3 ES 2849187T3 ES 11830662 T ES11830662 T ES 11830662T ES 11830662 T ES11830662 T ES 11830662T ES 2849187 T3 ES2849187 T3 ES 2849187T3
Authority
ES
Spain
Prior art keywords
hla
molecule
drb1
peptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11830662T
Other languages
English (en)
Spanish (es)
Inventor
Haruo Sugiyama
Shinji Sogo
Masayoshi Sato
Ryuki Kitamoto
Yoshihiro Goto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Application granted granted Critical
Publication of ES2849187T3 publication Critical patent/ES2849187T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES11830662T 2010-10-05 2011-10-04 Método para activar células T auxiliares Active ES2849187T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010225806 2010-10-05
PCT/JP2011/072874 WO2012046730A1 (ja) 2010-10-05 2011-10-04 ヘルパーｔ細胞の活性化方法

Publications (1)

Publication Number Publication Date
ES2849187T3 true ES2849187T3 (es) 2021-08-16

Family

ID=45927725

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11830662T Active ES2849187T3 (es) 2010-10-05 2011-10-04 Método para activar células T auxiliares

Country Status (21)

Country Link
US (2) US10654892B2 (OSRAM)
EP (1) EP2626418B8 (OSRAM)
JP (3) JP6134139B2 (OSRAM)
KR (3) KR102171794B1 (OSRAM)
CN (2) CN105802910A (OSRAM)
AR (1) AR083295A1 (OSRAM)
AU (1) AU2011313327B2 (OSRAM)
BR (1) BR112013008230A2 (OSRAM)
CA (1) CA2813557C (OSRAM)
CO (1) CO6710946A2 (OSRAM)
EA (1) EA037547B1 (OSRAM)
ES (1) ES2849187T3 (OSRAM)
IL (2) IL225536B (OSRAM)
MX (2) MX361299B (OSRAM)
MY (1) MY170306A (OSRAM)
NZ (2) NZ609460A (OSRAM)
PH (1) PH12013500654A1 (OSRAM)
SG (3) SG189287A1 (OSRAM)
TW (2) TW201623616A (OSRAM)
WO (1) WO2012046730A1 (OSRAM)
ZA (1) ZA201303056B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696027A4 (en) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
ES2849187T3 (es) * 2010-10-05 2021-08-16 Int Inst Cancer Immunology Inc Método para activar células T auxiliares
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
WO2014042226A1 (ja) * 2012-09-12 2014-03-20 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
KR102158225B1 (ko) * 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2014157692A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
CN106029699B (zh) * 2014-02-26 2019-07-19 泰来有限公司 Wt1抗原性多肽和含有该多肽的抗肿瘤剂
KR102588853B1 (ko) 2014-12-25 2023-10-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 T 세포 집단의 개변 방법
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
EP3539974B1 (en) 2016-11-09 2023-03-29 Osaka University Method for modifying t cell population
JP7209963B2 (ja) * 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
CN111741972A (zh) * 2017-12-27 2020-10-02 大日本住友制药株式会社 Wt1衍生肽的缀合物和包含其的组合物
KR102267463B1 (ko) * 2018-02-15 2021-06-21 코쿠리츠다이가쿠호진 아사히카와 이카다이가쿠 암 항원 펩티드
CN112912387A (zh) * 2018-08-22 2021-06-04 弗雷德哈钦森癌症研究中心 靶向kras或her2抗原的免疫疗法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
EP1103564B1 (en) 1998-07-31 2009-01-07 International Institute of Cancer Immunology, Inc. Cancer antigens based on tumor suppressor gene wt1 product
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
IL142216A0 (en) 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
US20060165708A1 (en) 2001-06-29 2006-07-27 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
EP1536009B1 (en) 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restricted cancer antigen peptide
ES2538486T3 (es) 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
BRPI0406800B8 (pt) 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
US10500257B2 (en) 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
EP1696027A4 (en) 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
ES2556232T3 (es) 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
US7608769B2 (en) * 2004-05-12 2009-10-27 First Act, Inc. Packaged drum set
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
PT1961761E (pt) 2005-11-30 2010-12-16 Chugai Pharmaceutical Co Ltd Novos compostos peptídicos do tumor de wilms
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
US8759483B2 (en) 2006-02-22 2014-06-24 International Institute Of Cancer Immunology, Inc. HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
NZ601175A (en) 2006-12-28 2012-12-21 Int Inst Cancer Immunology Inc Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
PL2119778T3 (pl) 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
EP2857508A3 (en) 2007-03-05 2015-04-15 International Institute of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
ES2849187T3 (es) * 2010-10-05 2021-08-16 Int Inst Cancer Immunology Inc Método para activar células T auxiliares
KR102158225B1 (ko) 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법

Also Published As

Publication number Publication date
KR20200018738A (ko) 2020-02-19
BR112013008230A2 (pt) 2016-06-14
KR102079480B1 (ko) 2020-02-19
EA201390509A1 (ru) 2013-08-30
US20200354405A1 (en) 2020-11-12
EP2626418A4 (en) 2014-02-19
CO6710946A2 (es) 2013-07-15
SG189287A1 (en) 2013-05-31
EP2626418A1 (en) 2013-08-14
JP6134139B2 (ja) 2017-05-24
CA2813557C (en) 2021-05-04
NZ703560A (en) 2016-11-25
AU2011313327A1 (en) 2013-05-02
MX2018008436A (es) 2021-12-08
IL245440A0 (en) 2016-06-30
JP6298101B2 (ja) 2018-03-20
US12415833B2 (en) 2025-09-16
TW201623616A (zh) 2016-07-01
US20130266958A1 (en) 2013-10-10
EP2626418B8 (en) 2021-03-24
AU2011313327B2 (en) 2015-10-22
NZ609460A (en) 2015-07-31
US10654892B2 (en) 2020-05-19
PH12013500654A1 (en) 2013-05-06
AR083295A1 (es) 2013-02-13
CN103298928B (zh) 2016-04-20
CN103298928A (zh) 2013-09-11
KR102171794B1 (ko) 2020-10-29
EA037547B1 (ru) 2021-04-12
SG10202108581TA (en) 2021-09-29
MX2013003884A (es) 2013-07-05
JP2018093870A (ja) 2018-06-21
MX361299B (es) 2018-11-30
JPWO2012046730A1 (ja) 2014-02-24
IL225536A0 (en) 2013-06-27
JP2017006120A (ja) 2017-01-12
KR20140009168A (ko) 2014-01-22
CA2813557A1 (en) 2012-04-12
EP2626418B1 (en) 2020-12-09
TW201217525A (en) 2012-05-01
SG10201508252PA (en) 2015-11-27
MY170306A (en) 2019-07-17
TWI608099B (zh) 2017-12-11
WO2012046730A1 (ja) 2012-04-12
ZA201303056B (en) 2013-12-23
KR20190034359A (ko) 2019-04-01
IL225536B (en) 2019-03-31
CN105802910A (zh) 2016-07-27

Similar Documents

Publication Publication Date Title
ES2849187T3 (es) Método para activar células T auxiliares
ES2805337T3 (es) Método para activar células T auxiliares
ES2387685T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
DK2341142T3 (en) HLA-A * 1101-restricted WT1 peptide or pharmaceutical composition comprising this
KR20160029127A (ko) 종양 항원 펩티드
HK1188465B (en) Method for activating helper t cell
HK1188465A (en) Method for activating helper t cell